These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 31663154)
1. A novel approach to support implementation of biosimilars within a UK tertiary hospital. Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154 [TBL] [Abstract][Full Text] [Related]
2. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study. Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL; Lancet Rheumatol; 2024 Jul; 6(7):e438-e446. PubMed ID: 38843858 [TBL] [Abstract][Full Text] [Related]
3. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988 [TBL] [Abstract][Full Text] [Related]
4. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System. Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847 [TBL] [Abstract][Full Text] [Related]
5. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK. Tarallo M; Onishchenko K; Alexopoulos ST J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527 [No Abstract] [Full Text] [Related]
6. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related]
8. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA. Kearsley-Fleet L; Rokad A; Tsoi MF; Zhao SS; Lunt M; Watson KD; ; Hyrich KL Rheumatology (Oxford); 2023 Dec; 62(12):3849-3857. PubMed ID: 36943379 [TBL] [Abstract][Full Text] [Related]
9. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis. Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804 [TBL] [Abstract][Full Text] [Related]
10. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. Aladul MI; Fitzpatrick RW; Chapman SR BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242 [TBL] [Abstract][Full Text] [Related]
11. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. Bakalos G; Zintzaras E Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802 [TBL] [Abstract][Full Text] [Related]
12. A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. Moorkens E; Vulto AG; Kent J; McClure L; Boldero R; Vanhove T; Simoens S; Huys I BioDrugs; 2021 Jan; 35(1):75-87. PubMed ID: 33306186 [TBL] [Abstract][Full Text] [Related]
13. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730 [TBL] [Abstract][Full Text] [Related]
15. A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis. Kumar N; Follestad T; Sen HN; Austeng D Am J Ophthalmol; 2021 May; 225():178-184. PubMed ID: 33121931 [TBL] [Abstract][Full Text] [Related]
16. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174 [TBL] [Abstract][Full Text] [Related]
17. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab. Fitzgerald T; Melsheimer R; Lafeuille MH; Lefebvre P; Morrison L; Woodruff K; Lin I; Emond B Biologics; 2021; 15():1-15. PubMed ID: 33442230 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088 [TBL] [Abstract][Full Text] [Related]
19. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study. Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624 [TBL] [Abstract][Full Text] [Related]
20. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]